金达威｜调研要点：多特倍斯26年加大投入，看好代工厂VB改善趋势（20260127） 1辅酶Q10：目前价格处于合理区间（不会引发过多竞争），12月辅酶Q10价格有所下降，1-2月价格回升需求旺 盛，预计26年量升价减，希望毛利长期保持45%-50%。 2‼代工厂VB：#预计后续收入加速。 目前只有片剂和硬胶囊，预计4月开始软胶囊产线。 #VB目前工艺 金达威｜调研要点：多特倍斯26年加大投入，看好代工厂VB改善趋势（20260127） 1辅酶Q10：目前价格处于合理区间（不会引发过多竞争），12月辅酶Q10价格有所下降，1-2月价格回升需求旺 盛，预计26年量升价减，希望毛利长期保持45%-50%。 2‼代工厂VB：#预计后续收入加速。 目前只有片剂和硬胶囊，预计4月开始软胶囊产线。 ①抖音在做跨境产品管控，公司优势突出； ②美国代工厂加大投入，全产业链能力优势突出（即便下游利润较薄，但是原料代工有优势）。 4变更募集资金用途： ①智慧工厂：后续会做自己品牌的保健品，可能用国内已有品牌金乐心，聚焦物美价廉和二三线城市，不做全品 类而是聚焦有原料的产品（例如辅酶Q10、PQQ等）。 #VB目前工艺、交付期已经 ...

Group 1: Company Overview - The company primarily engages in the research, production, and sales of nutritional health foods (including raw materials and finished products) and feed additives [2][3] - The production of health food raw materials and feed additives mainly occurs domestically, with a high export ratio; finished health food products are primarily produced and sold overseas, showing significant growth through cross-border e-commerce [3] Group 2: Product Development and Market Position - The company utilizes synthetic biology as a foundational technology for large-scale production of various raw materials, including Coenzyme Q10, NMN, NADH, Vitamin K2, and others [3] - Coenzyme Q10 holds the largest global market share, demonstrating notable cost and scale advantages [3] - The company aims to reduce production costs for products like astaxanthin, DHA, and EPA to enhance market competitiveness [3] Group 3: Brand and Sales Strategy - The company owns two major health food brands, Doctor's Best and Zipfizz, with production capabilities for capsules, tablets, and powders [3][4] - Doctor's Best is a well-known health brand in North America, showing steady growth, while Zipfizz maintains stable performance with new products developed for the U.S. market [4] - The marketing strategy for domestic health food business focuses on market insights, product strategy, resource integration, and data-driven upgrades to create market-leading products [4] Group 4: Financial Performance - The company's performance growth in the first half of 2025 is primarily attributed to increased sales of Coenzyme Q10, vitamins, and domestic health products [3]

Group 1: Company Operations - The company has successfully completed a 1.5 times expansion of its coenzyme Q10 raw material production line, with new fermentation tanks successfully tested and currently maintaining a strong production and sales momentum [2][3] - The price of Vitamin A has decreased due to market fluctuations, while DHA products have improved competitiveness through technological upgrades and market promotion, laying a solid foundation for future market expansion [2][3] - Other raw material products such as astaxanthin and Vitamin K2 are showing significant positive trends [3] Group 2: Market Expansion and Product Development - The company's health food finished product business is expanding well in the domestic market, benefiting from the rapid development of the domestic health consumption industry [3] - The overseas subsidiary VitaBest's soft capsule production line is under construction and is expected to be operational in the second half of the year; Zipfizz functional beverages will introduce four new flavors and a new "YOU" ready-to-drink product series [3] Group 3: Regulatory and Market Challenges - The current tariff rate for coenzyme Q10, Vitamin A, Vitamin D3, and Vitamin K2 exported to the U.S. is 20%. The company has mitigated the tariff impact by raising sales prices or having downstream customers bear the tariff costs; the sales proportion of vitamin products in the U.S. is small, limiting the overall impact [3] Group 4: Marketing Strategies - The company plans to develop marketing strategies for end-nutrition health products based on industry characteristics, market demand, brand positioning, and resource integration capabilities, utilizing market insights and data-driven approaches to create market-leading products [3] Group 5: Synthetic Biology Applications - The company employs synthetic biology as a foundational technology for the large-scale production of various raw material products, including coenzyme Q10, NMN, NADH, Vitamin K2, nattokinase, PQQ, SAMe, DHA, and ARA, while also exploring new products such as astaxanthin, algal oil EPA, glutathione, inositol, calcium pantothenate, and biological sweeteners [3]